News and Announcements
Cellmid’s Clinical Study Published
- Published March 02, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Cellmid Limited (ASX: CDY) is pleased to advise that a manuscript describing the screening approach and clinical study carried out by Cellmid’s wholly owned subsidiary, Advangen Limited, has been published in the journal Clinical, Cosmetic, and Investigational Dermatology.
KEY TAKEAWAYS:
- The paper also describes the results of the blinded, placebo controlled clinical study of topical formulations containing the lead inhibitor in men and women. The paper can be accessed via the Journal website.
- Advangen’s technology is based around the inhibition of FGF5, an important molecule in the hair cycle that signals hair follicles to stop producing hair and rest.
- The peer-reviewed publication of these data represents an important step for the Company’s subsidiary, Advangen, and strengthens the position in the market of its products as effective hair loss treatments based on validated scientific rationale.
The lead compound identified through the screening method, named MTP3, has been shown to be almost seven times more effective in inhibiting FGF5 than previous extracts and is now included in all évolis® branded products. The data generated through the compound screening is also the subject of a patent application, currently under examination.
“The identification of single molecule inhibitors rather than whole botanical extracts represents a significant improvement in the precision of the Company’s évolis® hair loss treatments, and resulted from a substantial body of work by our dedicated Japanese research team”, said the study’s lead author Dr Dominic Burg. “The compelling clinical results highlight the utility of évolis® products against pattern hair loss in both men and women” he added.
Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.
Company Updates
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
